The Filing Desk

Cytokinetics vs 4D Molecular Therapeutics

Cytokinetics CYTK · 4D Molecular Therapeutics FDMT · Biotechnology

Cytokinetics reported revenue of $88 million in fiscal 2025, about the same as 4D Molecular Therapeutics' $85 million in fiscal 2025. Cytokinetics' revenue grew 376.6% in its latest year, and 4D Molecular Therapeutics' grew 230194.6%. Cytokinetics had an operating margin of -695.4%, against -187.2% at 4D Molecular Therapeutics. Free cash flow was −$535 million at Cytokinetics and −$110 million at 4D Molecular Therapeutics.

Side by side

Cytokinetics4D Molecular Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$88M$85M
Revenue growth376.6%230,194.6%
Revenue growth a year, last 5 years9.5%44.3%
Gross margin——
Operating margin−695.4%−187.2%
Net margin−891.6%−164.4%
Free cash flow−$535M−$110M
Free cash flow margin−607.5%−128.7%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count—7.4%
Last close$56.13$12.23
P/E at the last close——
Insider trades, last 12 monthssold $51.3 million—
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Cytokinetics4D Molecular Therapeutics
Operating margin
Percent of revenue
Cytokinetics4D Molecular Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Cytokinetics4D Molecular Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Cytokinetics and 4D Molecular Therapeutics pages.